UMPIRE Trial: the polypill proves effective in treating high risk patients.

A polypill is an interesting strategy for cardiac patients requiring multiple drugs. This trial involved 2138 patients from 28 sites in India and Europe with an event risk higher than 15% at 5 years of conventional therapy or a polypill which combined aspirin, statin, lisinopril and atenolol/hydrochlorothiazide in fixed doses. At a 24 month follow up the polypill had significantly better adherence (86% vs. 65% p<0,0001), and better control of blood pressure (p=0,0005) and LDL cholesterol (p=0,0005).

Conclusion: the polypill showed improvement in adherence and control of risk factors vs. the standard therapy.

Comment: In addition to improving adherence and therefore reducing cardiovascular events in the population, this kind of treatment could contribute to reduce public healthcare costs, especially in developing countries.

Descargar (PDF, Unknown)

Simon A Thom
2012-11-05

Original title: Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE)

*

Top